Different aspects of molecular design of ADAPTs for imaging and targeted therapy applications were investigated and the most promising variant of ADAPT was recently evaluated for SPECT imaging of HER2 expression in breast cancer in a clinical study [20,21,22,23,24,25]. The gene discussed is ERBB2; the disease is breast carcinoma.